Worry no more, since scientists have found a drug which prevents epilepsy seizures and can also stop multiple sclerosis sufferers going blind.
UK has more than 100, 000 people with MS and half of those experience acute optic neuritis at some point.
A sickness called Optic neuritis damages the nerves by taking information from the eye to the brain and can trigger sudden blindness, foggy vision or pain.
University College London conducts a clinical trial that examines 86 people showing early symptoms of acute optic neuritis
For three months the group that took the epilepsy drug phenytoin was found, however, they had 30% less damage to the nerve fiber layer compared to those who had been given a medication.
MS has no cure at this moment in time. Though there are some treatments which can slow progression of disability, yet they are not worthy for everybody.
The neurological condition sees the immune system attack myelin, a substance surrounding the nerves, which leads to delays and confusion in messages sent from the brain and spinal cord to parts of the body.
It affects almost three times as many women over men, is unpredictable and can leave people useless not being able to see or move.
University College London Hospital, Dr Raj Kapoor, said: “About half of people with MS has experience acute optic neuritis at some point in their life. These are assuring results and, if our findings are supported by larger studies, could lead to a new treatment that protects nerves from being damage caused in both optic neuritis and all over the central nervous system in MS.”
Head of bio-medical research at the MS Society, Dr Emma Gray, added: “We are really gallant to have co-funded this trial, which is the result of many years of corroborate research by Dr Kapoor and his team.
“Examining the optic nerve gives us a window to the brain so we can get an idea about how a drug like phenytoin could protect nerve cells.
“Our aim is to ensure people with MS have access to effective medication, including medication which can slow, stop or reverse the accumulation of disability and this trial takes us one step closer to that goal.”